Skip to main content
IMS Events Main banner
Rate ePoster

    Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)

    Category: Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)

    RESCUE-LATAM Study: Real-world Evaluation of Salvage Combinations for Unmet needs in Expose and refractory multiple myeloma in LATAM Settings

    (PA-486) RESCUE-LATAM Study: Real-world Evaluation of Salvage Combinations for Unmet needs in Expose and refractory multiple myeloma in LATAM Settings

    Friday, September 19, 2025

    Introduction:      

    Background:     Multiple myeloma (MM) is a chronic, relapsing malignancy requiring multiple lines of therapy. As patients (pts) become exposed and refractory to standard drug classes, options narrow. Salvage combinations remain poorly characterized, especially outside clinical trials. In LATAM, access to novel agents varies across countries, and real-world evidence is scarce.





    Aims: To describe real-world treatment patterns in triple-class-exposed (TCE) and refractory (TCR) MM pts, assess access to novel therapies in five LATAM countries, and report clinical characteristics, overall response rates (ORR), progression-free survival (PFS), and overall survival (OS).

    Methods:   



    Methods:     Retrospective, multicenter, observational study across Argentina, Chile, Uruguay, Mexico, and Peru. Adult TCE/TCR MM pts were included. Variables analyzed: demographics, salvage therapy patterns, ORR, PFS, and OS after anti-CD38 refractoriness (T0). Statistical analyses used SPSS v.27, p< 0.05.

    Results:   



    Results:     202 pts were included; median age at T0 was 62 years, 53% male. ISS-3 was present in 33%, and del(17p) in 11%. Median prior lines: 3; 72% had undergone autologous stem cell transplant. All pts were TCE; 27% were penta-refractory. 93.5% received subsequent therapy, but only 8.4% were treated with bispecific antibodies. No consistent standard of care was observed. Salvage regimens included: PI/steroid (6/202), IMiD/alkylator (12/202), PI/alkylator (45/202), PI/IMiD (38/202), IMiD/steroid (5/202), chemotherapy (24/202), and others. With median follow-up of 36.9 months, ORR was 54.5% (≥VGPR in 28%). Median PFS and OS from T0 were 12.1 and 13.3 months, respectively. PFS rate at 18 months was 28.4% (95% CI: 21.1–35.7); OS rate at 18 months was 44.3% (95% CI: 36.5–52.1). Disease progression accounted for 81 of 111 deaths.

    Conclusions:   



    Conclusion:     This is the first real-world registry of RRMM in LATAM, focused on TCE pts. It reveals wide heterogeneity in salvage regimens and limited use of novel agents, especially bispecific antibodies. These findings underscore the urgent need to expand access to emerging therapies and develop regionally adapted strategies to improve outcomes.